Risk Factors that Affects Progression of Type 2 Retinopathy of Prematurity

Ga Hee Han; Ji Woong Chang

doi:10.3341/jkos.2019.60.10.953

Journal List > J Korean Ophthalmol Soc > v.60(10) > 1135389

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Han and Chang: Risk Factors that Affects Progression of Type 2 Retinopathy of Prematurity

Original Article

Journal of the Korean Ophthalmological Society 2019; 60(10): 953-958.

Published online: 21 October 2019

DOI: https://doi.org/10.3341/jkos.2019.60.10.953

Risk Factors that Affects Progression of Type 2 Retinopathy of Prematurity

Ga Hee Han, MD^1,², Ji Woong Chang, MD^1,²

¹Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

²Graduate Program in Cognitive Science, Yonsei University, Seoul, Korea.

Address reprint requests to Ji Woong Chang, MD. Department of Ophthalmology, Inje University Ilsan Paik Hospital, #170 Juhwa-ro, Ilsanseo-gu, Goyang 10380, Korea. Tel: 82-31-910-7240, Fax: 82-31-911-7241, naizzima@hanmail.net

Received 4 April 2019 Revised 4 May 2019 Accepted 24 September 2019

The Korean Ophthalmological Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To identify risk factors that affect the development of type 2 retinopathy of prematurity (ROP) and progression to type 1 or threshold ROP requiring treatment.

Methods

The medical records of premature infants born with a birth weight ≤1,500 g or a gestational age ≤32 weeks were retrospectively reviewed. Potential risk factors were divided into systemic and ophthalmic factors and analyzed by univariate and multivariate logistic regression analyses.

Results

Three hundred and twenty-four eyes met the screening criteria. Among them, 41 eyes (12.65%) progressed to type 2 ROP and 21 eyes (6.48%) received treatment after progression to type 1 or threshold ROP. The systemic risk factor associated with progression from type 2 ROP was periventricular leukomalacia and the ophthalmic factor was the existence of nasal ROP at the time of diagnosis of type 2 ROP.

Conclusions

Careful examination was needed when type 2 ROP with periventricular leukomalacia or nasal ROP developed because there was a high probability of progression and treatment.

Keywords: Retinopathy of prematurity, Risk factors, Type 2 retinopathy of prematurity

Figures and Tables

Table 1

Baseline characteristics of the participants

Values are presented as mean ± standard deviation (range) unless otherwise indicated.

Table 2

Development and progression of retinopathy of prematurity

ROP = retinopathy of prematurity.

Table 3

Systemic risk factor evaluation by univariate logistic regression analysis for type 2 retinopathy of prematurity development and retinopathy of prematurity progression and treatment

ROP = retinopathy of prematurity; OR = odds ratio; CI = confidence interval; CPAP = continuous positive airway pressure; RBC = red blood cell.

^*Logistic regression analysis, statistically significant (p < 0.05).

Table 4

Ophthalmic risk factor evaluation by univariate logistic regression analysis for retinoapthy of prematurity progression and tretment from type 2 retinopathy of prematurity

ROP = retinopathy of prematurity; CI = confidence interval; OR = odds ratio.

*Logistic regression analysis; statistically significant (p < 0.05).

Notes

^{Conflicts of Interest} The authors have no conflicts to disclose.

References

1. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: II. Report of cases-clinical aspects. Trans Am Ophthalmol Soc. 1942; 40:262–284.

2. Clemett R, Darlow B. Results of screening low-birth-weight infants for retinopathy of prematurity. Curr Opin Ophthalmol. 1999; 10:155–163.

3. Good WV, Hardy RJ, Dobson V, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005; 116:15–23.

4. Lucey JF, Dangman B. A reexamination of the role of oxygen in retrolental fibroplasia. Pediatrics. 1984; 73:82–96.

5. Garner A. The role of hyperoxia in the aetiology of retinopathy of prematurity. Doc Ophthalmol. 1990; 74:187–193.

6. Avery GB, Glass P. Retinopathy of prematurity: progress report. Pediatric annals. 1988; 17:528–533.

7. Wilkinson AR, Haines L, Head K, et al. UK retinopathy of prematurity guideline. Eye (Lond). 2009; 23:2137–2139.

8. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of Cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988; 106:471–479.

9. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol. 2001; 119:1110–1118.

10. Good WV, Hardy RJ. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology. 2001; 108:1013–1014.

11. An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol. 1984; 102:1130–1134.

12. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1993; 100:230–237.

13. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005; 123:991–999.

14. Cho YU, Koo BS. Incidence and risk factors in retinopathy of prematurity. J Korean Ophthalmol Soc. 1993; 34:851–859.

15. Cho YS, Kim TY, Kwon OW. Prognostic factors of retinopathy of prematurity. J Korean Ophthalmol Soc. 1995; 36:45–51.

16. Rhim WI, Lew HL, Yun YS. Clinical features of risk factors and regression of retinopathy of prematurity. J Korean Ophthalmol Soc. 2002; 43:1199–1205.

17. Choi SH, Ham DI. Incidence and risk factors of retinopathy of prematurity in extremely low birth weight and very low birth weight infants. J Korean Ophthalmol Soc. 2006; 47:918–926.

18. Darlow BA, Horwood LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol. 1992; 6:62–80.

19. Chen M, Citil A, McCabe F, et al. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neonatology. 2011; 99:125–132.

20. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS. 2000; 4:343–347.

21. Holmström G, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity--a population-based study. Acta Ophthalmol Scand. 1998; 76:204–207.

22. Yang MB, Donovan EF, Wagge JR. Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity. J AAPOS. 2006; 10:253–261.

23. Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann Acad Med Singapore. 2005; 34:169–178.

24. Gunn TR, Easdown J, Outerbridge EW, Aranda JV. Risk factors in retrolental fibroplasia. Pediatrics. 1980; 65:1096–1100.

25. Hammer ME, Mullen PW, Ferguson JG, et al. Logistic analysis of risk factors in acute retinopathy of prematurity. Am J Ophthalmol. 1986; 102:1–6.

26. Slidsborg C, Jensen A, Forman JL, et al. Neonatal risk factors for treatment-demanding retinopathy of prematurity: a Danish national study. Ophthalmology. 2016; 123:796–803.

27. Purohit DM, Ellison RC, Zierler S, et al. Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National collaborative study on patent ductus arteriosus in premature infants. Pediatrics. 1985; 76:339–344.

28. Brown DR, Biglan AW, Stretavsky MM. Retinopathy of prematurity: the relationship with intraventricular hemorrhage and bronchopulmonary dysplasia. J Pediatr Ophthalmol Strabismus. 1990; 27:268–271.

29. Ancel PY, Goffinet F; EPIPAGE-2 Writing Group, et al. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr. 2015; 169:230–238.

30. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007; 196:147.

31. Bolisetty S, Dhawan A, Abdel-Latif M, et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics. 2014; 133:55–62.

32. Linder N, Haskin O, Levit O, et al. Risk factors for intraventricular hemorrhage in very low birth weight premature infants: a retrospective case-control study. Pediatrics. 2003; 111:590–595.

33. Procianoy RS, Garcia-Prats JA, Hittner HM, et al. An association between retinopathy of prematurity and intraventricular hemorrhage in very low birth weight infants. Acta Paediatr Scand. 1981; 70:473–477.

34. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92:529–534.

35. Kusters CD, Chen ML, Follett PL, Dammann O. "Intraventricular" hemorrhage and cystic periventricular leukomalacia in preterm infants: how are they related. J Child Neurol. 2009; 24:1158–1170.

36. Kuwabara T, Cogan DG. Studies of retinal vascular patterns I Normal architecture. Arch Ophthalmol. 1960; 64:904–911.

37. Nissenkorn I, Kremer I, Cohen S, Ben-Sira I. Nasal versus temporal preretinal vasoproliferation in retinopathy of prematurity. Br J Ophthalmol. 1989; 73:747–749.

38. Lee DC, Kim KS, Kim YC. A review of nasal retinopathy of prematurity cases. J Korean Ophthalmol Soc. 2011; 52:1485–1489.

TOOLS

Similar articles